leadf
logo-loader
viewCytoDyn Inc.

CytoDyn provide update on their path to approval for treatment of COVID-19

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive to provide an update on how and when they expect to have approval for Leronlimab for Covid treatment. 

Pourhassan also told Proactive about what the recent decision by the FDA to approve Remdesivir as a treatment for Covid-19 means for their company moving forward.

Quick facts: CytoDyn Inc.

Price: 2.66 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.52 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn achieves 75% enrollment for its severe-to-critical coronavirus...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotechnology company has achieved the enrollment of 293 patients with severe-to-critical coronavirus symptoms, meeting the criteria for a second interim analysis by the Data Safety Monitoring Committee (DSMC). Pourhassan says...

5 days, 23 hours ago

2 min read